AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04365894 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transformative learning theory
Description: According to the transformative learning theory, learning methods in education should include four activities as investigate, collaborative, higher-order thinking and interactive learning activities
Study NCT03428841 — intervention group
Intervention type: PROCEDURE
Intervention: Audiometry
Study NCT00628758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort TBH - Turbuhaler
Description: Symbicort Single Inhaler Therapy ( Turbuhaler 160/4.5 microgram, 1 inhalation bid + as needed)
Study NCT00628758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: beta-II-agonist, inhale steroid
Description: Salbulin inh. 200-400 dosage 100 microgram (mcg)/dosage Salbutamol Sustained Release(SR)capsule 4 mg/8 mg Salbutol tablet (tb) 2 mg Salbutol forte syrup 2 mg/5 ml Ventolin tb, syrup, intravenous(IV),5mgx10 ampule(amp) Ventolin inhaler (inh) 200 dosage, 100 mcg/dosage Ventolin nebul 2.5 mg Volmax tb 4 mg/8 mg Vent-o-sal inh 100 mcg/200 dosage Combivent inh 100 mcg/dosage Combivent neb 2.5 mg/dosage Bricanyl tb 2.5 mg Bricanyl durules ret tb 5 mg Bricanyl syrup 30mg Bricanyl inhaler 0.25 mg/dosage, 400 dosage Bricanyl turbuhaler 0.5 mg/dosage, 200dosage
Study NCT01564667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Training Protocol
Description: Attention Bias Modification computerized training sessions administered 2 times per week for 4 weeks making a total of 8 training sessions.
Study NCT01564667 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Bias Modification Training Protocol
Description: Attention Bias Modification computerized training sessions administered 2 times per week for 4 weeks making a total of 8 training sessions.
Study NCT03779893 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BioCoat® by Premier®.
Description: Bioactive pits and fissure sealant
Study NCT03779893 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: 3M™ Clinpro™ Sealant.
Description: conventional pits and fissure sealant
Study NCT03496727 — intervention group
Intervention type: PROCEDURE
Intervention: Serratus anterior plane block
Description: Serratus anterior plane block+patient controlled analgesia
Study NCT03496727 — intervention group
Intervention type: PROCEDURE
Intervention: Patient controlled analgesia
Description: Patient-controlled analgesia
Study NCT03181074 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study NCT00988260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix
Description: Ganirelix 0.125 mg subcutaneous daily (SC OD) for up to 14 days
Study NCT00988260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix
Description: Ganirelix 0.25 mg subcutaneous daily (SC OD) for up to 14 days
Study NCT00988260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix
Description: Ganirelix 0.5 mg subcutaneous daily (SC OD) for up to 14 days
Study NCT02535637 — intervention group
Intervention type: OTHER
Intervention: Exclusively breastfeed
Description: There is no intervention other than mothers must exclusively breastfeed.
Study NCT06377722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: This study tries to clarify whether Cabozantinib could be a safe and effective preoperative treatment in patients with advanced RCC who were candidates for removing a part or all of their kidney.
Study NCT00438893 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Dietary portfolio of cholesterol-lowering foods
Description: A plant based dietary portfolio providing plant sterols (1.0g/1000 kcal), soy protein (22.5g/1000 kcal, viscous fibers 10 g/1000 kcal and almonds 22.5g/1000 kcal)
Study NCT05100433 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonic irrigation
Description: Ultrasonic irrigation will be used as a complementary step to chemomechanical procedures to test whether it can improve root canal disinfection.
Study NCT04828369 — intervention group
Intervention type: PROCEDURE
Intervention: EUS-guided coil embolization combined with endoscopic cyanoacrylate injection
Description: (1) Standard diagnostic endoscopy was first performed. Fundal varices were assessed using the classification of Sarin's. (2) intraluminal water filling of the gastric fundus to use EUS to assess the anatomy of gastric varices, observe the blood flow, scan the portal venous system, left renal vein, confirm the location of the shunt, and measure the diameter of the shunt. (3) Punctured the gastric fundal variceal vein at the lower esophagus near the cardia and placed the coil into the shunt and immediately injected with sclerosant and cyanoacrylate under the guidance of EUS. (4) Sclerosant and cyanoacrylate were injected into the gastric fundal varices by a sandwich method (cyanoacrylate, sclerosant and cyanoacrylate) via endoscope. (5) After the injection, use color Doppler ultrasound to observe the blood flow in the variceal veins to evaluate the embolization effect.
Study NCT04828369 — intervention group
Intervention type: PROCEDURE
Intervention: balloon-occluded retrograde transvenous obliteration
Description: (1)A balloon occlusive catheter was inserted into the shunt via the right femoral vein. (2)Investigators performed angiography to evaluate the size and location of GV and the shunt during balloon occlusion. Shunt was occluded by Fogarty balloon. The diameter of the balloon was chosen according to the diameter of shunt. (3)Then investigators injected sclerosant into the portosystemic shunt. (4)Finally, the balloon left in place for 24 hours was gradually deflated when complete occlusion of blood flow of the target shunt was achieved.
Study NCT01469572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: Pasireotide is given as an injection.
Study NCT01469572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sir-sphere Radioembolization
Description: A catheter will be placed in a branch of the hepatic artery (liver) that supplies the tumor with blood. Radioactive beads will be injected into the tumor through the catheter.
Study NCT01469572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given orally every day for the duration of the study
Study NCT02675179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EOS
Description: Pelvimetry will be performed with the new EOS technique of diagnosis to measure the diameter of the basin.
Study NCT02675179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spiral CT pelvimetry
Description: Pelvimetry will be performed with the spiral CT technique. It is the technique usually used.
Study NCT03167164 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
Study NCT03167164 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Recombinant human anti-VEGF IgG1 monoclonal antibody
Study NCT03167164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study NCT03167164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: (SP-4-2)-diamminedichloroplatinum(II)
Study NCT03167164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study NCT03167164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione
Study NCT03167164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
Study NCT03167164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: 5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
Study NCT03167164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omega-3-acid ethyl esters
Description: Omega-3-acid ethyl esters
Study NCT03167164 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: radiation
Study NCT03167164 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Recombinant human super agonist interleukin-15 (IL-15) complex
Study NCT03167164 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051
Description: Ad5 \[E1-, E2b-\]-Brachyury
Study NCT03167164 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-MUC1
Study NCT03167164 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301
Description: Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
Study NCT03167164 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK
Description: NK-92 \[CD16.158V, ER IL-2\] (high-affinity activated Natural Killer cells)
Study NCT02939599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QCC374
Description: 0.015mg and 0.06mg
Study NCT01612377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone-Dipyridamole
Description: Oral, QD
Study NCT01612377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Oral QD Prednisone 5mg
Study NCT03338868 — intervention group
Intervention type: OTHER
Intervention: Musculoskeletal pain intensity
Description: evaluated with Visual Analog Scale
Study NCT02272946 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Canakinumab
Description: 150mg Canakinumab received subcutaneously
Study NCT02272946 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150mg Placebo received subcutaneously
Study NCT01015755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: combined therapy treatment
Description: mouth care
Study NCT00720577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: 40 Mg. tablet, 1 tablet daily
Study NCT00720577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: 50 mg., tablets, 1 tablet once daily
Study NCT00720577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 30 mg, tablet, 1 tablet once daily
Study NCT04532840 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryotherapy (Gymna Cryoflow ICE-CT)
Description: Cryotherapy (also called cryoablation) method was produced by James Arnot in England in 1945 to reduce the size of cancerous cells based on the theory that cold blood cells destroy the cells. Campbell White of New York City used cryotherapy as the first dermatological indication in early-stage epithelioma patients in 1890. Later in 1907, Whitehouse described the use of this method in diferent diseases such as pigmented nevus and lupus. In addition, he has published a case series of skin cancers in different face regions.
Study NCT04532840 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercising, Positioning and splinting, Pressure Therapy and Massage
Description: Exercising, Positioning and splinting, Pressure Therapy and Massage
Study NCT04532840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercising, Positioning and splinting, Pressure Therapy and Massage
Description: Exercising, Positioning and splinting, Pressure Therapy and Massage
Study NCT04794868 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CCTA-derived high risk plaque characteristics
Description: Presence of CCTA-derived high risk plaque characteristics
Study NCT04794868 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CFD-derived hemodynamic parameters
Description: CFD-derived hemodynamic parameters
Study NCT00178971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adjunctive treatment with buspirone
Description: buspirone 15-30 mg qd
Study NCT00178971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT01612377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Oral, QD prednisone 7.5mg
Study NCT01390480 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol
Description: weekly dose (based on 70 IU/kg bodyweight/day) orally
Study NCT01390480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: weekly dose (based on 70 IU/kg bodyweight/day) orally
Study NCT00091026 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study NCT00091026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT01880190 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Study NCT01880190 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HES 130/0.4 and Ringer's Lactate
Study NCT02626936 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dual-hormone closed-loop
Description: Interventions will be undertaken one to 5 days after sensor insertion. Subjects will be admitted at the research center at 7:00 am. Subject's pump will be substituted with the study pump and an additional pump containing glucagon will be installed. At 7:00, CLS will be initiated. At 9:00, a standardized breakfast (75g CHO) will be served. Study subjects will consume the same meal on the two intervention days. During the intervention, patients will be allowed to do sedentary activities. Patients will allowed to consume caffeine during the intervention, but will have to replicate their caffeine consumption on both interventions.The intervention day will end at 13:00.
Study NCT00091026 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00091026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study NCT03448900 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Description: Motivational interview (50 minutes), on-line self-help material, support e-mail, group therapy, and second motivational interview (20 minutes)
Study NCT03448900 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief advice
Description: Brief advice (5-10minutes) and a self-help pamphlet
Study NCT03396978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GnRHag
Description: Ovarian Hormone Suppression - the purpose of the intervention is not to study the drug, but the impact of the loss of ovarian hormones.
Study NCT03775590 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Water
Description: To evaluate using water in the treatment of atopic dermatitis
Study NCT03775590 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bleach
Description: To evaluate using water + dilute bleach in the treatment of atopic dermatitis
Study NCT03775590 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acetic acid
Description: To evaluate using water + vinegar in the treatment of atopic dermatitis
Study NCT04286464 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT01579552 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: survey, questionaire
Description: The intervention components (mailed tailored print materials followed by telephone-delivered Brief MI). Following enrollment into the study and completion of the informed consent form and baseline survey, participants will be randomized to the active intervention group or the attention control group. The data that will be used in the analysis will come from the baseline survey, medical records of breast imaging studies, and a 12-month follow-up questionnaire.
Study NCT01579552 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: survey, questionaire
Description: The intervention components (mailed tailored print materials followed by telephone-delivered Brief MI). Following enrollment into the study and completion of the informed consent form and baseline survey, participants will be randomized to the active intervention group or the attention control group. The data that will be used in the analysis will come from the baseline survey, medical records of breast imaging studies, and a 12-month follow-up questionnaire.
Study NCT04643795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGL-3196
Description: Once daily oral dose for 6 days
Study NCT01653002 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT00889395 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: MISC training for primary caregivers
Description: Caregivers of children in the intervention arm will undergo a year long training in MISC
Study NCT03304327 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and Yoga Training
Description: Centering and Breathing- Practice begins by turning attention to the breath to help participants make the transition from the busy, doing, outward focus of daily life into the mindful, balanced, internal focus central to yoga practice.~Practices:Breath awareness, the relaxed abdominal breath. Posture Practice-Warm up with the range-of-motion sequence to take the major joints of the body through their full range of motion.This is done lying down with the head on the floor; the head can be supported by a small, folded towel if desired.~Practices: Knee-to-chest sequence, Arms and Shoulders, Gentle Spinal Twist, Apanasana.~Standing Poses for Strength and Balance, to enhance function and confidence. Practices: Mountain Pose, Flying Crane Sequence, Tree Pose, Warrior 2 and Side Angle.~Relaxation- Practice concludes with guided relaxation to quiet the mind and calm the body.~Practices: Seated Mountain Pose, even breath, extended exhalation,Yoga Nidra.
Study NCT04915326 — intervention group
Intervention type: PROCEDURE
Intervention: rectal resection
Description: every patients will undergo to the appropriate rectal resection
Study NCT03024840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane: 1%\~2%
Study NCT03024840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol: 9-15 mg/kg/h
Study NCT04929418 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 10 km continuous running
Description: Trial participants will perform a 10 km continuous running exercise
Study NCT04929418 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 1.5 km continuous swimming
Description: Trial participants will perform a 1.5 km continuous swimming exercise.
Study NCT04568018 — intervention group
Intervention type: DRUG
Intervention: Surfactant
Description: Inhalation of surfactant emulsion at 150 mg
Study NCT03920878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept injected Pre- and Post-operatively
Description: Three injections of aflibercept before cataract surgery, and aflibercept injections after surgery within 14-21 days of the day of surgery (number of injections depends on clinical exam findings, visual acuity and retinal thickness).
Study NCT03920878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept injected intraoperatively
Description: Three injections of aflibercept before surgery and one injection of aflibercept during the course of the surgery by cataract surgeon.
Study NCT00270998 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Therapy
Description: Pelvic muscle training and exercises
Study NCT00270998 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravaginal Pessary
Description: Intravaginal pessary
Study NCT00270998 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pessary combined with behavioral therapy
Description: Intravaginal pessary and behavioral therapy
Study NCT02751021 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: pacemaker diagnostic algorithm
Description: evaluation of the respiratory disturbance index by measurement of transthoracic impedance variation, to detect sleep apnea
Study NCT02751021 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Attended cardiorespiratory sleep study
Description: sleep study with portable monitor resulting in the apnea hypopnea index, to confirm sleep apnea diagnosis
Study NCT04655209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: apply a-tDCS on the ipsilesional M1 followed by MT (M1-Seq)
Description: The participants in the M1-Seq group will first receive a-tDCS over ipsi-lesional M1 without any active arm practice for 20 minutes. For the next 20 minutes, the participants will start the MT, while the electrodes will be remained on the scalp with the stimulator off (sham tDCS condition). Then the electrodes will be removed, and the participants will receive additional 20 minutes of MT without tDCS followed by 30 minutes of functional task practice.
Study NCT04655209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: apply a-tDCS on the ipsilesional PMC followed by MT (PMC-Seq)
Description: The procedures for the PMC-Seq group will be the same as the M1-Seq, except that a-tDCS will be applied on ipsilesional PMC but not M1.
Study NCT04655209 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: MT only with sham tDCS (MT)
Description: For the MT group, the procedure will be the same as the other groups except that sham tDCS will be used for the first 40 minutes.